MRX 6

Drug Profile

MRX 6

Alternative Names: MRX-6

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Akari Therapeutics
  • Class Nonsteroidal anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Arachidonic acid inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Allergic contact dermatitis; Atopic dermatitis

Most Recent Events

  • 17 Feb 2015 Efficacy data from a phase II trial in Atopic dermatitis released by Celsus Therapeutics
  • 13 Jan 2015 Celsus Therapeutics completes enrolment in its phase II trial for Atopic dermatitis (In adolescents, In children) in Israel (9173659; NCT02031445)
  • 12 Jan 2015 FDA approves IND application for MRX 6 in Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top